Current report
Open the filing on sec.gov
Prelude Therapeutics Incorporated (PRLD)
Nasdaq: PRLD · Pharmaceutical Preparations · Wilmington, DE · filing with the SEC since 2016
The companyfiscal 2025, as filed
Revenue$12.1M+73.4%
Net income-$99.5M+21.8%
Earnings per share$-1.29+23.2%
Operating cash flow-$56.3M+45.3%
Cash$35.3M+182.6%
Debtn/a
Shareholders’ equity$68.6M-47.8%
Shares, diluted77.0M+1.5%
Return on equity-145.0%
The recordfrom its filings
Filings in 202643
Newest filingSep 10 · 8-K
Annual reportMar 10, 2026
Quarterly reportAug 11, 2026
Next report due10-Q by Nov 14
Insider sales, 12 months$0.00
Insider buys, 12 months$25.0M
Patents granted0
Filer categoryNon-accelerated filer<br>Smaller reporting company
Trailing twelve months to Jun 2026Revenue $22.4MNet income -$60.5MCash from operations -$33.3Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Quarterly report
Open the filing on sec.gov
Results released
Open the filing on sec.gov
Large holder notice
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.